News from this newspaper (Feng Wenping All Media Reporter Li Jiawen) In recent years, the Municipal Medical Insurance Bureau has taken multiple measures to effectively reduce the need for people to seek medical treatment through the implementation of centralized drug consumption, the reform of payment methods to reduce fees, and the negotiation of drug insurance to reduce the burden. burden.
The Municipal Medical Insurance Bureau made every effort to promote the implementation of the national centralized procurement of drugs and the inter-provincial alliance centralized procurement of drugs. The city implemented five batches of national centralized procurement of 218 kinds of drugs and two batches of inter-provincial alliance centralized procurement of 34 kinds of drugs. Product prices dropped by 53% on average; 58 types of cardiac coronary stents and coronary dilation balloons were collected and collected, with an average drop of 90%. In 2021, the burden of medical treatment for the masses will be reduced by 107 million yuan.
Through the establishment of the city’s DRG payment management platform, the city’s medical insurance designated medical institutions implement DRG simulation payment, forcing medical insurance designated medical institutions to strengthen internal management. In the third quarter of 2021, the city’s medical insurance co-ordination fund expenditure decreased by 5.09% compared with the second quarter, the total medical expenses of insured personnel decreased by 7.31%, and personal expenses decreased by 14.96%, achieving a win-win situation for hospitals, medical insurance and patients. From January 2022, the city’s 191 medical insurance designated medical institutions with hospital settlements will fully implement DRG payment.
In addition, the Municipal Medical Insurance Bureau promptly included the 119 “special drugs” and “life-saving drugs” added by the new negotiation of the National Drug List in 2020 into the scope of medical insurance payment. In 2021, the city will reimburse 67,970 nationally negotiated drugs, with a total cost of 80.71 million yuan, and the overall reimbursement ratio is 62%, reducing the drug burden of insured personnel by 50.37 million yuan.